RARE

#1571
Ultragenyx Pharmaceutical Inc.
23.39
+3.82%
版块:
基础:
利润货币:
日范围
23.39
23.39
年范围
18.41
43.22
日变化
+3.82%
每月变动
-6.29%
6个月变化
-22.16%
年变化
-43.88%
前一天收盘价
22.53
Open
23.39
Bid
Ask
Low
23.39
High
23.39
交易量
111
Open full chart

Financials

Overview 声明 Statistics Dividends
Quarterly Annual
  • Market Capitalization 2.31 B
  • Employee 1 371
  • Founded 2010
  • CEO Emil Kakkis
  • Website www.ultragenyx.com
  • Headquarter Delaware, United States
  • FIGI BBG001RWPDW6
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-3.95
Price to sales ratio
3.37
Dividends per share
—
Dividend yield %
—

Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA.

新闻